Shots:

• The P-II study evaluates dazodalibep (HZN-4920) vs PBO in 75 subjects with active, moderate-to-severe, adult-onset RA. Patients were randomized into four different dosing regimens
• The study met its 1EPs change from baseline in DAS28-CRP @Day 113 in all four dazodalibep dosing arms. The therapy was well tolerated
• In the P-II trial, the last dose of dazodalibep was given @Day 85 and follow-up data @Day 169 showed a prolonged and sustained benefit on disease activity. The study follows the P-Ib, multiple ascending dose study in patients with active moderate-to-severe RA

Ref: Horizon Therapeutics | Image: Horizon